All In Biotech

Drug Trial Radar · NCT03618043

Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer

A Phase I, Open-label Study to Assess the Safety and Tolerability of Ascending Doses of SH-1028 Tablets in Patients With Advanced Solid Cancer

Last checked: Nov 19, 2026Latest source record: Jan 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

14

Planned (sponsor's estimate)

Start

Sep 13, 2018

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Sponsor type
Industry
First posted
Aug 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label study of SH-1028 with dose escalation cohorts in locally advanced solid cancer patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent or standard treatment.

Conditions

  • Advanced Solid Cancer

Interventions

  • SH-1028Drug

    Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: Within the first 28 days of treatment
  2. Incidence of Dose Limiting Toxicity (DLT)Time frame: Within the first 28 days of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai east hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.